Myriad Genetics - MYGN Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month target prices for Myriad Genetics' shares. Their MYGN share price forecasts range from $22.00 to $32.00. On average, they predict the company's share price to reach $25.50 in the next year. This suggests a possible upside of 35.4% from the stock's current price.
View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts.

Myriad Genetics' stock was trading at $27.60 on January 1st, 2022. Since then, MYGN stock has decreased by 31.7% and is now trading at $18.84.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MYGN earnings forecast.

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Tuesday, November, 1st. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.12. The business had revenue of $156.40 million for the quarter, compared to analysts' expectations of $172.12 million. Myriad Genetics had a negative net margin of 11.69% and a negative trailing twelve-month return on equity of 4.86%.

Myriad Genetics issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of -$0.35--$0.30 for the period, compared to the consensus earnings per share estimate of -$0.06. The company issued revenue guidance of $668.00 million-$672.00 million, compared to the consensus revenue estimate of $692.18 million.

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (18.00%), Vanguard Group Inc. (11.26%), State Street Corp (5.75%), Artisan Partners Limited Partnership (3.30%), Dimensional Fund Advisors LP (3.00%) and Disciplined Growth Investors Inc. MN (2.81%). Insiders that own company stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee, S Louise Phanstiel and Walter Phd Gilbert.
View institutional ownership trends.

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MYGN stock can currently be purchased for approximately $18.84.

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.53 billion and generates $690.60 million in revenue each year. The company earns $-27,200,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

The company employs 2,400 workers across the globe.

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.